Omeros Co. (NASDAQ:OMER) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Omeros Co. (NASDAQ:OMER) have received an average rating of “Moderate Buy” from the five analysts that are covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $22.50.

Several research firms recently weighed in on OMER. Rodman & Renshaw began coverage on Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective for the company. D. Boral Capital reissued a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Thursday, January 16th. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Finally, StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th.

Hedge Funds Weigh In On Omeros

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its holdings in Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares in the last quarter. MML Investors Services LLC raised its holdings in shares of Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 3,000 shares in the last quarter. SPC Financial Inc. acquired a new position in shares of Omeros in the 3rd quarter worth approximately $77,000. SG Americas Securities LLC acquired a new position in shares of Omeros in the 3rd quarter worth approximately $80,000. Finally, AQR Capital Management LLC acquired a new position in shares of Omeros in the 2nd quarter worth approximately $105,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Stock Performance

OMER opened at $9.01 on Friday. The company has a market cap of $522.13 million, a PE ratio of -3.90 and a beta of 2.01. The stock has a 50-day moving average of $9.65 and a 200-day moving average of $6.13. Omeros has a 52-week low of $2.61 and a 52-week high of $13.60.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.